wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q33812445-3E99DA35-619B-44F8-A6B3-C75CFFE34F05
Q33812445-3E99DA35-619B-44F8-A6B3-C75CFFE34F05
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33812445-3E99DA35-619B-44F8-A6B3-C75CFFE34F05
Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.
P2860
Q33812445-3E99DA35-619B-44F8-A6B3-C75CFFE34F05
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33812445-3E99DA35-619B-44F8-A6B3-C75CFFE34F05
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
986a76e4b035290f2dfe3a3e39dd11f4fb164f72
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.